3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Uveal Melanoma
1
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
11
Specimen Handling
4
X-Rays
3
Nivolumab
3
Ipilimumab
3
Immunoglobulin G
3
Biopsy
3
temsirolimus
2
sargramostim
2
epacadostat
2
capivasertib
2
Taxes
2
Paclitaxel
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Disulfides
2
Cyclophosphamide
2
Blood Specimen Collection
2
zimberelimab
1
veliparib
1
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
spartalizumab
1
sonidegib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
niraparib
×
Dermatologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts